AVPR1B anticorps (AA 23-120) (Alexa Fluor 555)

N° du produit ABIN1393397

Détail du produit anti-AVPR1B anticorps (Alexa Fluor 555)

Antigène: AVPR1B (Arginine Vasopressin Receptor 1B (AVPR1B))

Épitope: AA 23-120

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp AVPR1B est conjugé à/à la Alexa Fluor 555

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Homologie: Human,Mouse,Rat,Dog,Cow,Pig,Horse

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human AVP Receptor V3

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur AVPR1B

Antigène: AVPR1B (Arginine Vasopressin Receptor 1B (AVPR1B))

Autre désignation: AVPR1B/AVP Receptor V3 (AVPR1B Produits)

Synonymes: anticorps LOC443050, anticorps AVPR1B, anticorps si:ch211-125a15.3, anticorps AVPR3, anticorps V3/V1b, anticorps VIBR, anticorps VPR3, anticorps arginine vasopressin receptor 1B, anticorps arginine vasopressin receptor 1Ab, anticorps AVPR1B, anticorps avpr1ab, anticorps Avpr1b

Sujet:

Synonyms: Antidiuretic hormone receptor 1b, Arginine vasopressin receptor 1B, Arginine vasopressin receptor 3, AVPR V1b, AVPR V3, Avpr1b, AVPR3, Pituitary vasopressin receptor 3, V1bR, V1BR_HUMAN, Vasopressin V1b receptor, Vasopressin V3 receptor, VPR3.

Background: Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Pathways: Regulation of Systemic Arterial Blood Pressure by Hormones